Avastin in Combination With Temozolomide for Unresectable or Multifocal Glioblastoma Multiformes and Gliosarcomas
Avastin and Temozolomide
Astrocytome+15
+ Maladies du cerveau
+ Néoplasmes cérébraux
Étude thérapeutique
Résumé
Date de début de l'étude : 1 août 2007
Date à laquelle le premier participant a commencé l'étude.Subjects have histologically confirmed WHO gr IV primary malignant glioma that is unresectable/multifocal. This is Phase II study where up to 41 subjects will receive up to 4 cycles of Avastin \& Temozolomide. Avastin administered at 10 mg/kg every 14 days beginning a minimum of 7 days after biopsy/28 days after craniotomy. Temozolomide dosed at 200 mg/m2 daily for 5 days in 28-day cycle. Patients will receive up to 4 cycles of Avastin \& Temozolomide, then proceed with standard XRT. Study will use 2-stage "minimax" study design in which 21 subjects are accrued during 1st stage, with possibility that additional 20 patients accrued during 2nd stage. In initial Phase I \& II trials, 4 potential Avastin-associated safety signals were identified: hypertension, proteinuria, thromboembolic events, \& hemorrhage. Avastin-associated adverse events in Phase III trials include congestive heart failure, GI perforations, wound healing complications, \& arterial thromboembolic events. Most common toxicity associated with Temozolomide has been mild myelosuppression.
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.41 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Traitement
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.À partir de 18 ans
Tranche d'âge des participants éligibles à participer.Volontaires sains non autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Conditions
Pathologie
Critères
Inclusion Criteria: Patients have histologically confirmed diagnosis of WHO gr IV primary malignant glioma. Patients will be unresectable or have multifocal disease. * Age ≥ 18years \& life expectancy of \>12 weeks * Evidence of measurable primary CNS neoplasm on contrast enhanced MRI. * Interval of \<1 week between prior biopsy/4 weeks from surgical resection \& enrollment on protocol * Karnofsky ≥60% * Hemoglobin ≥9g/dl, ANC ≥1,500 cells/microliter, platelets ≥125,000 cells/microliter * Serum creatinine ≤1.5 mg/dl, serum SGOT \& bilirubin ≤1.5 x ULN * For patients on corticosteroids, they must have been on stable dose for 1 week prior to entry, if clinically possible, \& dose should not be escalated over entry dose level * Signed informed consent approved by IRB prior to patient entry * No evidence of \> grade 1 CNS hemorrhage on baseline MRI/CT scan * If sexually active, patients will take contraceptive measures for duration of treatments Exclusion Criteria: * Pregnancy/breast feeding * Co-medication that may interfere with study results * Active infection requiring IV antibiotics * Prior or current Treatment w XRT/chemo for brain tumor, irrespective of grade of tumor * Evidence of \> grade 1 CNS hemorrhage on baseline MRI or CT scan Avastin-Specific Concerns: * Inadequately controlled hypertension * Any prior history of hypertensive crisis/hypertensive encephalopathy * New York Heart Association Grade II or \> congestive heart failure * History of myocardial infarction/unstable angina \< 6 months prior to study enrollment * History of stroke/transient ischemic attack \< 6 months prior to study enrollment * Significant vascular disease * Symptomatic peripheral vascular disease * Evidence of bleeding diathesis/coagulopathy * Major surgical procedure, open biopsy,/significant traumatic injury within 28 days prior to study enrollment/anticipation of need for major surgical procedure during course of study * Core biopsy/other minor surgical procedure, excluding placement of vascular access device, \<7 days prior to study enrollment * History of abdominal fistula, GI perforation, /intra-abdominal abscess \<6 months prior to study enrollment * Serious, non-healing wound, ulcer, or bone fracture * Proteinuria at screening as demonstrated by either * UPC ratio ≥1.0 at screening OR * Urine dipstick for proteinuria ≥2+ * Known hypersensitivity to any component of Avastin * Pregnant/lactating. Use of effective means of contraception in subjects of child-bearing potential * Current, ongoing treatment with full-dose warfarin or its equivalent
Plan de l'étude
Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.Un seul groupe d'intervention est désigné dans cette étude
Cette étude ne comporte pas de groupe placebo.
Groupes de traitement
Groupe I
ExpérimentalObjectifs de l'étude
Objectifs principaux
Centres d'étude
Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.Cette étude comporte 1 site
Duke University Health System
Durham, United StatesOuvrir Duke University Health System dans Google Maps